Opthea Appoints Parisa Zamiri, MD, PhD, as Chief Medical Officer

Australian drug developer Opthea announced Oct. 8 that it had appointed Parisa Zamiri, MD, PhD, as chief medical officer.

Zamiri, an ophthalmologist, has clinical experience in medical retina, immunology, and inflammation. She most recently served as chief medical officer at Complement Therapeutics and Graybug Vision. Prior to that, she served as vice president, global head of clinical development, and therapeutic area head for ophthalmology at Novartis.

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase III clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains. Topline data are expected in mid-2025.